{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Konar M"],"funding":["NCRR NIH HHS","NIAID NIH HHS"],"pagination":["627-36"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3719908"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["208(4)"],"pubmed_abstract":["<h4>Background</h4>Factor H (fH) binding protein (fHbp) is part of vaccines developed for prevention of meningococcal serogroup B disease. More than 610 fHbp amino acid sequence variants have been identified, which can be classified into 2 subfamilies. The extent of cross-protection within a subfamily has been difficult to assess because of strain variation in fHbp expression.<h4>Methods</h4>Using isogenic mutant strains, we compared cross-protective serum antibody responses of mice immunized with 7 divergent fHbp variants in subfamily B, including identification numbers (ID) 1 and 55, which were chosen for vaccine development.<h4>Results and conclusions</h4>In the presence of the human complement downregulator fH, the ability of the anti-fHbp antibodies to deposit sufficient complement C3"],"journal":["The Journal of infectious diseases"],"pubmed_title":["Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines."],"pmcid":["PMC3719908"],"funding_grant_id":["AI 99125","R01 AI046464","R01 AI 70955","R01 AI099125","C06 RR016226","R01 AI082263","AI 82263","C06 RR 16226","R01 AI070955","AI 46464"],"pubmed_authors":["Konar M","Beernink PT","Granoff DM"],"additional_accession":[]},"is_claimable":false,"name":"Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.","description":"<h4>Background</h4>Factor H (fH) binding protein (fHbp) is part of vaccines developed for prevention of meningococcal serogroup B disease. More than 610 fHbp amino acid sequence variants have been identified, which can be classified into 2 subfamilies. The extent of cross-protection within a subfamily has been difficult to assess because of strain variation in fHbp expression.<h4>Methods</h4>Using isogenic mutant strains, we compared cross-protective serum antibody responses of mice immunized with 7 divergent fHbp variants in subfamily B, including identification numbers (ID) 1 and 55, which were chosen for vaccine development.<h4>Results and conclusions</h4>In the presence of the human complement downregulator fH, the ability of the anti-fHbp antibodies to deposit sufficient complement C3","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Aug","modification":"2025-04-26T14:04:10.333Z","creation":"2019-03-27T01:13:30Z"},"accession":"S-EPMC3719908","cross_references":{"pubmed":["23715659"],"doi":["10.1093/infdis/jit239"]}}